Changes in Alcohol Use Among Adults with Cancer Participating in the ECOG-ACRIN EAQ171CD Tobacco Treatment Trial.

Authors

Angela Wangari Walter, JoRean D Sicks, Alexander Taurone, Sai Priyanka Mellacheruvu, Rachel L Rosen, Brett M Goshe, Ilana F Gareen, Benjamin A Herman, Autumn W Rasmussen, Alona Muzikansky, Susan Regan, Douglas E Levy, Michael A Thompson, Laura Malloy, Irina Gonzalez, Lucy Finkelstein-Fox, Nathan D Munson, Molly M Greenwade, David M King, Bharat Jenigiri, Brian L Burnette, Alyssa D Throckmorton, Martha S Tingen, Ruth C Carlos, Lynne I Wagner, Jamie S Ostroff, Elyse R Park

Published in

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. Sep 09, 2026. Epub Sep 09, 2026.

Abstract

Alcohol and tobacco use are known carcinogens. Treating alcohol and tobacco co-use can improve treatment and survivorship outcomes among patients diagnosed with cancer.
We conducted a post hoc analysis of ECOG-ACRIN EAQ171CD trial participants within the NCI Community Oncology Research Program (NCORP), examining changes in alcohol use among adults receiving the virtual sustained treatment (VST) for tobacco use intervention versus enhanced usual care (EUC; Quitline referral). Multivariable logistic regression assessed changes in alcohol use disorder risk at 3 and 6 months using the AUDIT-C.
At baseline, participants (N = 305) were classified as no risk (31%), low/minimal risk (38%), moderate risk (23%), or high risk (8%) for alcohol use disorder. The mean age was 55.6 years, participants smoked for an average of 33 years, and 18% had alcohol-associated tumors. Participants randomized to EUC were more likely to shift to a lower alcohol risk category than those in the VST arm at 3 months (39% vs 27%) and 6 months (33% vs 27%). There was no significant difference in the odds of shifting to a lower risk category for VST vs EUC at 3 months (adjusted OR = 0.56, 95% CI 0.26-1.18, p = 0.125) or at 6 months (adjusted OR = 0.57, 95% CI 0.25-1.28, p = 0.172).
Patients diagnosed with cancer and engaging in alcohol and tobacco co-use can achieve reductions in alcohol use and risk.
Integrating tailored, co-use-focused strategies into cessation programs may improve changes in modifiable risk behaviors.

PMID:
42714936
Bibliographic data and abstract were imported from PubMed on 10 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.